ERBB2 and cancer: Overexpression of neuromedin U in drug-sensitive cells promoted resistance to HER-targeting drugs; the peptide increased HER-2 and EGFR expressions along with drug resistance, and neuromedin U attenuation weakened cancer growth and metastasis [185].